|
1 Tsai HP,Kuo PH,Liu CC,Wang JR.Respiratory Viral Infections among Pediatric Inpatients and Outpatients in Taiwan from 1997 to 1999.Clinical Cicrobiology.2001,Jan:111-118. 2 Lai CKW, Kim YY, Kuo SH, Spencer M, Williams AE,On behalf of the Asthma Insights and Reality in As, (2006). Cost of asthma in the Asia-Pacific region.ERR 15:10-16 3 Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases of Children 1986;140:543–6. 4 Parrott RH, Kim WH, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E,Chanock RM:Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. American Journal of Epidemiology 1973; 98:289–300 5 Hall CB: Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia 2000; pp 2084–2111. 6 Wickman M, Farahmand BY, Persson P-G, Pershagen G: Hospitalization for lower respiratory disease during 20 years among under-5-year -old children in Stockholm County: a population-based survey. European Respiratory Journal 1998; 11: 366–370. 7 Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL: Risk of respiratory syncytial virus for infants from lowincome families in relationship to age, sex, ethnic group, and maternal antibody level. Journal of Pediatrics.1981; 98:708–715. 8 Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD: Risk factors for respiratory syncytial virusassociated lower respiratory illnesses in the first year of life. American Journal of Epidemiology.1991; 134 :1135–1151. 9 Allport T, Davies E, Wells C, et al. Ribavarin and bronchiolitis: variation in use in the UK [letter]. Arch Dis Child 1997;76: 385-392. 10 Canfield S, Simoes E. Prevention of respiratory syncytial virus (RSV) infection: RSV immuneglobulin intravenous and palivizumab. Ped Ann 1999; 28: 507-14. 11 Kristensen K, Dahm T, Frederiksen PS, Ibsen J, Iyore E, Jensen AM, Kjaer BB, Olofsson K, Pedersen P, Poulsen S: Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatric Infectious Disease Journal.1998;17:996–1000. 12 Purcell K, Fergie J. Driscoll Children’s Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatric InfectiousDisease Journal 2004;23:418–23. 13 Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants.J Pediatr 2003 Nov;14(5):S150-6. 14 American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998 Nov;102(5):1211-6. 15 Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immuneoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls.Pediatrics 1995;95:500-5. 16 Wang EE, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection. The Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001725. DOI: 10.1002/14651858.CD001725.pub2. 17 The American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112(6):1442-1446. 18 Krilov LR. Respiratory syncytial virus infection. http://www.emedicine.com/PED/topic2706.htm. 19 Feltes TF, Cabalka AK, Meissner HC et al.Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr.2003; 143(4), 532–540. 20 Yount LE, Mahle MT. Economic analysis of Palivizumab in infants with congenital heart disease.Pediatrics 2004;114:1606–11. 21 http://www.doh.gov.tw/statistic/data/衛生動向/95/95.htm. 22 Sanchez PJ. Immunoprophylaxis for respiratory syncytial virus. Pediatric Infectious Disease Journal 2002;21:473–8. 23 資料來源:醫藥網http://www.medicinenet.com/palivizumab-injection/article.htm 24 IMpact study group. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from Respiratory syncytial virus infection in high risk infants.Pediatrics 1998; 102: 531-7. 25 Eric A.F. Simoes et al, Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing, J Pediatr 2007;151:34-42. 26 Grimaldi M, Gouyon B, Sagot P et al.Palivizumab efficacy in preterm infants with geatational age ≤ 30 weeks without bronchopulmonary dysplasia. Pediatr.Pulmonol. 2007;42, 189–192 27 Mitchell I, Tough S, Gillis L, Majaesic C.Beyond randomized controlled trials: a“real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatric Pulmonology.2006;41(12), 1167–1174. 28 Shireman TI, Braman KS. Impact and cost–effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid’s high-risk children. Arch. Pediatr. Adolesc.Med.2002;156(12), 1251–1255. 29 Vogel AM, McKinlay MJ, Ashton Tet al.Cost–effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health 2002; 38(4):352–357. 30 Meberg A, Bruu AL. Respiratory syncytialvirus infections in congenital heart defects hospitalizations and costs. Acta Paediatrica 2006; 95(4): 404–406 31 Heikkinen T, Valkonen H, Lehtonen L,Vainionpaa R, Ruuskanen O. Hospitaladmission of high risk infants for respiratory syncytial virus infection:implications for palivizumab prophylaxis.Arch. Dis. Child. Fetal Neonatal Ed.2005; 90(1): F64–F68. 32 Stevens TP, Sinkin RA, Hall CB,Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr.Adolesc. Med. 2000; 154(1): 55–61. 33 Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost.Scott. Med. J.2003; 48(4): 108–110. 34 Reeve CA, Whitehall JS, Buettner PG et al.Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health 2006;42(5): 253–258. 35 Farina D, Rodriguez SP, Bauer G et al.Respiratory syncytial virus prophylaxis: cost–effective analysis in Argentina. Pediatr. Infect. Dis. J. 2002; 21(4): 287–291. 36 Roeckl-Wiedmann I, Liese JG, Grill E et al. Economic evaluation of possible Prevention of RSV-related hospitalizations in premature infants in Germany.Eur. J.Pediatr. 2003;162(4):237–244 . 37 Duppenthaler A, Gorgievski-Hrisoho M,Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med. Wkly 2001;131(11–12): 146–151. 38 Joffe S, Ray GT, Escobar GJ, Black SB,Lieu TA. Cost–effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104(3 Pt 1): 419–427. 39 McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr. Pulmonol.2002;34(4): 262–266. 40 Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol. Young 2005; 15(3): 251–255. 41 Elhassan NO, Sorbero ME, Hall CB,Stevens TP, Dick AW. Cost–effectiveness analysis of palivizumab in premature infants without chronic lung disease.Arch. Pediatr. Adolesc. Med.2006; 160(10),1070–1076 . 42 Gaetano Chirico,Roberto Ravasio,Urbano Sbarigia. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian J. Pediatr 2009,35:4 43 Clinical Therapeutics /Volume 30 Number 4 2008Cost-Effectiveness of Palivizumab Against Respiratory Syncytial Viral Infection in High-Risk Children in Austria.2008; 30(4):749-760 44 Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.Pharmacoeconomics 2007;25(1), 55–71 . 45 Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K .The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain. An Pediatr (Barc). 2006 Oct;65(4):316-24 46 根據中華民國90年~96年的出生通報平均值為基準來計算推估.資料來源:行政院衛生署國民健康局 統計資料. http://olap.bhp.doh.gov.tw/search/ListHealth0.aspx? menu=2&mode=7&year=96.
47 Navas L, Wang E, Carvalho V, Robinson J, and the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) (JM Langley member of group). Improved outcome of respiratory syncytial virus infection in a higt-risk hospitalized population of Canadian. J Pediatr. 1992;121:348-354 48 Huang YC,Lin TY,Chang LY,Wong KS,Ning SC.Epidemiology of respiratory virus infection among paediatric inpatients in northern Taiwan. Eur J Pediatr 2001,160:581-582. 49 Development of The Immune System in Very Low Borth Weight(Less 1500 g)Premature Infants:Concentrations of Plasma Immunoglobuli -ns and Patterns of Infections.Pediatr Res.1986,20:899-904. 50 資料來源:內政部戶政司,統計資料查詢 http://www.ris.gov.tw/ch4/static/st20-7.xls. 51 Lee JT,Chang LY,Wang LC,Kao CL,Shao PL,Lu CY,Lee PI,Chen JM,Lee CY,Huang LM.Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005—seasonality, clinical characteristics, and disease burden.Micromtiol Immunol Infect. 2007,40:293-301. 52 漫談早產兒與氣喘. 台灣兒童過敏氣喘及免疫學會學會通訊. Vol.5 No.3 September 2004. 53 根據中華民國96年內政部統計處男性平均壽命73.7歲為基準來做計算 推估.資料來源:內政部統計處.我國生命表.
|